ArticlePneumonia (Nathan Qld.)2022
Estimated incidence of respiratory hospitalizations attributable to RSV infections across age and socioeconomic groups.
Article in Pneumonia (Nathan Qld.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07171164 (Motivate Vaccinate Activate), which is not on this map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Motivate Vaccinate Activate: An Effectiveness-Implementation Trial to Assess the Impact of a Multi-Component Community-Based Intervention to Increase RSV Vaccine Uptake Among Latino Older Adults
Who cites it
58 citing papers in PubMed, 95 citations in OpenAlex.
- Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and Revaccination.The Journal of infectious diseases · 2024Trial
- Respiratory Syncytial Virus Hospitalizations in Adults ≥50 Years of Age and Those With Congestive Heart Failure or Chronic Obstructive Pulmonary Disease Exacerbations, 2018-2020.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Observational
- From triplex to tetraplex: evaluation of the diagnostic accuracy of the new Roche Cobas Liat SARS-CoV-2, influenza A/B & RSV assay.Journal of clinical microbiology · 2026Observational
- A comprehensive look at Respiratory Syncytial Virus (RSV): from pathogenesis to prevention.Tropical diseases, travel medicine and vaccines · 2026Review
- Disease burden estimates in economic evaluation studies of Respiratory Syncytial Virus (RSV) maternal immunization: a systematic review protocol.Systematic reviews · 2026Article
- Postmarketing safety surveillance for GSK's AS01BMJ open · 2026Article
- Aptamers targeting respiratory syncytial virus showed high inhibitory activity by blocking the G protein.Acta pharmaceutica Sinica. B · 2026Article
- Incidence of RSV- and Influenza-Associated Hospitalizations With Community-Acquired Pneumonia and Other Acute Respiratory Infection Among Adults in Japan in 2022-2024: APSG-J2 Study.Influenza and other respiratory viruses · 2026Article
- Estimating the burden of RSV- and influenza-associated ED visits, hospitalizations, ICU admissions, and deaths across age and socioeconomic groups in New York State, 2005-2019.BMC infectious diseases · 2026Article
- Research on age-stratified prevention and control strategies for pediatric RSV infection based on disease burden disparities.BMC infectious diseases · 2026Article
- Estimated Incidence of All-Cause Respiratory Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus Infections in Adults in Finland between 2011 and 2019: A Retrospective Database Study.Journal of epidemiology and global health · 2026Article
- Article
- Article
- Public Health Impact and Cost-Effectiveness of Adjuvanted RSVPreF3 Vaccination among Adults in the USA Aged 50-59 Years at Increased Risk of Severe RSV Disease.Infectious diseases and therapy · 2025Article
- Urban contact patterns shape respiratory syncytial virus epidemics with implications for vaccination.Science advances · 2025Article
- The top 100 most cited articles on pediatric respiratory syncytial virus pneumonia over the last 30 years: a bibliometric analysis.Tropical medicine and health · 2025Article
- Incidence of Respiratory Syncytial Virus-Associated Hospitalization Among Adults in Ontario, Canada, 2017-2019.The Journal of infectious diseases · 2025Article
- Burden and Characteristics of RSV-Associated Hospitalizations in Switzerland: A Nationwide Analysis from 2017 to 2023.Viruses · 2025Article
- Estimated Incidence of Hospitalisations and Deaths Attributable to Respiratory Syncytial Virus Infections in Adults in Norway between 2010 and 2019: A Time-Series Modelling Study.Journal of epidemiology and global health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundSurveillance for respiratory syncytial virus (RSV) likely captures just a fraction of the burden of disease. Understanding the burden of hospitalizations and disparities between populations can help to inform upcoming RSV vaccine programs and to improve surveillance.
methodsWe obtained monthly age-, ZIP code- and cause-specific hospitalizations in New York, New Jersey, and Washington from the US State Inpatient Databases (2005-2014). We estimated the incidence of respiratory hospitalizations attributable to RSV by age and by socioeconomic status using regression models. We compared the estimated incidence and the recorded incidence (based on ICD9-CM) of RSV hospitalizations to estimate the under-recorded ratio in different subpopulations.
resultsThe estimated annual incidence of respiratory hospitalizations due to RSV was highest among infants < 1 year of age with low socioeconomic status (2800, 95% CrI [2600, 2900] per 100,000 person-years). We also estimated a considerable incidence in older adults (≥ 65 years of age), ranging from 130 to 960 per 100,000 person-years across different socioeconomic strata. The incidence of hospitalization recorded as being due to RSV represented a significant undercount, particularly in adults. Less than 5% of the estimated RSV hospitalizations were captured for those ≥ 65 years of age.
conclusionsRSV causes a considerable burden of hospitalization in young children and in older adults in the US, with variation by socioeconomic group. Recorded diagnoses substantially underestimate the incidence of hospitalization due to RSV in older adults.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.